Effects of a Supervised Training Program on Functional Capacity in Patients With HF and Cardiorenal Syndrome

Launched by FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL CLÍNICO DE VALENCIA · Oct 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a supervised training program can help improve the physical abilities of patients with heart failure and cardiorenal syndrome, which is a condition where both the heart and kidneys are not functioning well. Patients who join the study will be randomly assigned to either continue with their usual medical care or to take part in a training program that includes both aerobic (like walking or cycling) and strength exercises. The main goal is to see if this training helps them improve their exercise capacity over a 12-week period.

To be eligible for the trial, participants must be at least 18 years old and diagnosed with heart failure, based on recent guidelines. They should also have signs of cardiorenal syndrome, which means their kidneys are not working well alongside their heart condition. Patients need to be stable but still experiencing symptoms like fatigue or shortness of breath. Throughout the study, participants will undergo tests to measure their heart and lung function. It's important to note that the trial is not yet open for recruitment, so interested individuals will need to wait for more information on how to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with heart failure according to 2021 ESC guidelines for Heart Failure.
• • Evidence of cardiorenal syndrome, defined as coexistent very high risk chronic kidney disease (CKD) (estimated glomerular filtration rate \[eGFR\] \<30 ml/min/1.73m2 or eGFR 30 to 44 ml/min/1.73m2 and Urine Albumin-Creatinine Ratio \[uACR\] \>30 mg/g) or rapidly progressive CKD (loss of \>5 ml/min/1.73m2 in one year).
• • Stable symptomatic heart failure patients (New York Heart Association functional class II-III/IV) during the last month.
• • Age ≥ 18 years old.
• • Willing to provide written informed consent.
• Exclusion Criteria:
• • Inability to perform a valid baseline cardiopulmonary exercise test.
• • Significant primary severe valve disease that is considered the main symptom driver.
• • Effort angina or signs of ischemia during CPET.
• • Primary cardiomyopathies.
• • Cardiac transplantation.
• • Any other comorbidity with a life expectancy of less than one year.